NCT Number: NCT06279442
This is a retrospective observational cohort study. The clinical, pathological and treatment data of participants identified with adrenocortical carcinoma from the year 2000 onwards will be evaluated. Participants recruited for this study will be identified at the participating sites.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Pronutrir - Suporte Nutricional e Quimioterapia, Fortaleza, Ceará, Brazil
Adrenocortical carcinoma is one of the rarest neoplasms in the world. In Brazil, especially in the South and Southeast regions, the incidence of adrenocortical tumors is around 15 times higher than in the rest of the world, largely attributed to the significant prevalence of the TP53-R337H germline mutation in this population. In view of this characteristic, the clinical and epidemiological characterization of this cohort, as well as the identification of prognostic factors, is of great importance. The starting point for this project was the cohort of 66 participants with adrenal carcinoma included in the final project of the medical residency in clinical oncology at the A.C. Camargo Cancer Center by student Rafael Haikal dos Santos Abduch. The aim is to include case studies from the main Brazilian site that have followed up and treated patients with adrenal carcinoma.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Throughout the study period, an average of 18 months.
This measure aims to capture essential demographic attributes of individuals in Brazil diagnosed with adrenocortical carcinoma. It will include details such as age distribution in years, gender representation, geographic distribution, height in meters, weight in kilograms, as well as racial and ethnic demographics . These insights will contribute to a comprehensive understanding of the demographic landscape of adrenocortical carcinoma within the Brazilian population.
Time frame: Throughout the study period, an average of 18 months.
This measure aims to capture essential clinical attributes of individuals in Brazil diagnosed with adrenocortical carcinoma. It will include relevant clinical factors such as tumor stage, hormone secretion status, and treatment modalities. These insights will contribute to a comprehensive understanding of the clinical landscape of adrenocortical carcinoma within the Brazilian population.
Contact information is provided by the study sponsor or research team.
Giana Blume Corssac
CONTACT
Laura Voelcker
CONTACT
Latin American Cooperative Oncology Group
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06607692
Adrenal Cortex Diseases, Adrenal Cortex Neoplasms
Boadilla del Monte, Madrid, Spain
View Trial DetailsNCT04897321
Adrenal Cortex Diseases, Adrenal Cortex Neoplasms
Memphis, Tennessee, United States
View Trial DetailsNCT07195734
Carcinoma, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Tucson, Arizona, United States
View Trial DetailsNCT07489066
Bronchial Neoplasms, Carcinoma
Hinsdale, Illinois, United States
View Trial Details